Yuriko Hamaguchi

653 total citations
20 papers, 495 citations indexed

About

Yuriko Hamaguchi is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Oncology. According to data from OpenAlex, Yuriko Hamaguchi has authored 20 papers receiving a total of 495 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 15 papers in Endocrinology, Diabetes and Metabolism and 6 papers in Oncology. Recurrent topics in Yuriko Hamaguchi's work include Diabetes Treatment and Management (12 papers), Metabolism, Diabetes, and Cancer (11 papers) and Peptidase Inhibition and Analysis (3 papers). Yuriko Hamaguchi is often cited by papers focused on Diabetes Treatment and Management (12 papers), Metabolism, Diabetes, and Cancer (11 papers) and Peptidase Inhibition and Analysis (3 papers). Yuriko Hamaguchi collaborates with scholars based in Japan and United States. Yuriko Hamaguchi's co-authors include Takashi Nomiyama, Takako Kawanami, Makito Tanabe, Tomoko Tanaka, Toshihiko Yanase, Yuichi Terawaki, Ryoko Motonaga, Tsuyoshi Horikawa, Yoko Tsutsumi and Kazuki Nabeshima and has published in prestigious journals such as PLoS ONE, Diabetes and Biochemical and Biophysical Research Communications.

In The Last Decade

Yuriko Hamaguchi

19 papers receiving 495 citations

Peers

Countries citing papers authored by Yuriko Hamaguchi

Since Specialization

Citations

This map shows the geographic impact of Yuriko Hamaguchi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuriko Hamaguchi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuriko Hamaguchi more than expected).

Fields of papers citing papers by Yuriko Hamaguchi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuriko Hamaguchi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuriko Hamaguchi. The network helps show where Yuriko Hamaguchi may publish in the future.

Co-authorship network of co-authors of Yuriko Hamaguchi

This figure shows the co-authorship network connecting the top 25 collaborators of Yuriko Hamaguchi. A scholar is included among the top collaborators of Yuriko Hamaguchi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuriko Hamaguchi. Yuriko Hamaguchi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Inhibitory Effect of Pyra–Metho–Carnil on the Differentiation and Maturation of Macrophages in Normal and Cancer Microenvironments 2024 ·Anticancer Research ·(unknown), (unknown), Kazumasa Yoshida, Yuriko Hamaguchi, (unknown), (unknown), Shuhei Ishikura, Michitaka Nakano, (unknown), (unknown), Mikiko Aoki, Shohta Kodama, Senji Shirasawa, Toshiyuki Tsunoda	0
2	Sodium-glucose cotransporter 2 inhibitor canagliflozin attenuates lung cancer cell proliferation in vitro 2021 ·Diabetology International ·(unknown), Shin-ichi Yamashita, Takashi Nomiyama, Takako Kawanami, Yuriko Hamaguchi, Toru Shigeoka, Tsuyoshi Horikawa, Yuki Tanaka, Toshihiko Yanase, Daiji Kawanami, Akinori Iwasaki	32
3	High-mobility group box 2 protein is essential for the early phase of adipogenesis 2021 ·Biochemical and Biophysical Research Communications ·Hidetaka Morinaga, (unknown), Tomoko Tanaka, Makito Tanabe, Yuriko Hamaguchi, Toshihiko Yanase	4
4	Combined treatment with glucagon-like peptide-1 receptor agonist exendin-4 and metformin attenuates breast cancer growth 2021 ·Diabetology International ·Yuki Tanaka, (unknown), Takako Kawanami, Yuriko Hamaguchi, Tsuyoshi Horikawa, Toru Shigeoka, Toshihiko Yanase, Daiji Kawanami, Takashi Nomiyama	9
5	Pemafibrate, a PPAR alpha agonist, attenuates neointima formation after vascular injury in mice fed normal chow and a high-fat diet 2020 ·Heliyon ·Tsuyoshi Horikawa, Takako Kawanami, Yuriko Hamaguchi, Yuki Tanaka, (unknown), (unknown), Yuichi Takashi, Hiroyuki Takahashi, Makito Tanabe, Toshihiko Yanase, Daiji Kawanami, Takashi Nomiyama	10
6	Activation of overexpressed glucagon‐like peptide‐1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression 2020 ·Journal of Diabetes Investigation ·Toru Shigeoka, Takashi Nomiyama, Takako Kawanami, Yuriko Hamaguchi, Tsuyoshi Horikawa, Tomoko Tanaka, Shinichiro Irie, Ryoko Motonaga, (unknown), Makito Tanabe, Kazuki Nabeshima, Masatoshi Tanaka, Toshihiko Yanase, Daiji Kawanami	24
7	Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice 2019 ·Biochemistry and Biophysics Reports ·Hiroyuki Takahashi, Takashi Nomiyama, Yuichi Terawaki, (unknown), Takako Kawanami, Yuriko Hamaguchi, Tomoko Tanaka, Ryoko Motonaga, Takashi Fukuda, Makito Tanabe, Toshihiko Yanase	41
8	Selective androgen receptor modulator, S42 has anabolic and anti-catabolic effects on cultured myotubes 2019 ·Biochemistry and Biophysics Reports ·(unknown), Tomoko Tanaka, Yuriko Hamaguchi, (unknown), Ryoko Motonaga, Makito Tanabe, Takashi Nomiyama, Hajime Nawata, Toshihiko Yanase	14
9	1954-P: Combined Treatment with Exendin-4 and Metformin Attenuates Breast Cancer Growth 2019 ·Diabetes ·Yuki Fujimura, Takashi Nomiyama, (unknown), Takako Kawanami, Yuriko Hamaguchi, Tomoko Tanaka, Toshihiko Yanase	1
10	SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation 2019 ·Endocrine Journal ·(unknown), Takashi Nomiyama, Tomohiro Numata, Takako Kawanami, Yuriko Hamaguchi, (unknown), Tsuyoshi Horikawa, (unknown), (unknown), Ryoko Motonaga, Makito Tanabe, Ryuji Inoue, Toshihiko Yanase, Daiji Kawanami	63
11	Selective Androgen Receptor Modulator S42 Suppresses Prostate Cancer Cell Proliferation 2018 ·Endocrinology ·Takako Kawanami, Tomoko Tanaka, Yuriko Hamaguchi, Takashi Nomiyama, Hajime Nawata, (unknown)	7
12	Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Attenuates Prostate Cancer Cell Proliferation via Phosphorylation of MKP-1 2018 ·Diabetes ·Takako Kawanami, Takashi Nomiyama, Yuriko Hamaguchi, Tomoko Tanaka, Toshihiko Yanase	1
13	GLP-1 Receptor Agonist Exendin-4 Attenuates NR4A Orphan Nuclear Receptor NOR1 Expression in Vascular Smooth Muscle Cells 2018 ·Journal of Atherosclerosis and Thrombosis ·Hiroyuki Takahashi, Takashi Nomiyama, Yuichi Terawaki, Takako Kawanami, Yuriko Hamaguchi, Tomoko Tanaka, Makito Tanabe, Dennis Bruemmer, Toshihiko Yanase	18
14	SGLT2 Inhibitor Ipragliflozin Induces Breast Cancer Apoptosis via Membrane Hyperpolarization and Mitochondria Dysfunction 2018 ·Diabetes ·(unknown), Takashi Nomiyama, Tomohiro Numata, Takako Kawanami, Yuriko Hamaguchi, Tomoko Tanaka, Ryuji Inoue, Toshihiko Yanase	6
15	Exendin-4, a Glucagonlike Peptide-1 Receptor Agonist, Attenuates Breast Cancer Growth by Inhibiting NF-κB Activation 2017 ·Endocrinology ·(unknown), Takashi Nomiyama, (unknown), Takako Kawanami, Yoko Tsutsumi, Yuriko Hamaguchi, Tsuyoshi Horikawa, Yasuteru Yoshinaga, Shin-ichi Yamashita, Tomoko Tanaka, Yuichi Terawaki, Makito Tanabe, Kazuki Nabeshima, Akinori Iwasaki, Toshihiko Yanase	62
16	Augmented Growth Hormone Secretion and Stat3 Phosphorylation in an Aryl Hydrocarbon Receptor Interacting Protein (AIP)-Disrupted Somatotroph Cell Line 2016 ·PLoS ONE ·Takashi Fukuda, Tomoko Tanaka, Yuriko Hamaguchi, Takako Kawanami, Takashi Nomiyama, Toshihiko Yanase	12
17	GLP-1 action attenuates breast cancer growth and progression 2016 ·Diabetes Research and Clinical Practice ·(unknown), Takashi Nomiyama, (unknown), Yasuteru Yoshinaga, Shinichi Yamashita, Takako Kawanami, Yuriko Hamaguchi, Tomoko Tanaka, Akinori Iwasaki, Toshihiko Yanase	1
18	Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth 2015 ·PLoS ONE ·Yoko Tsutsumi, Takashi Nomiyama, Takako Kawanami, Yuriko Hamaguchi, Yuichi Terawaki, Tomoko Tanaka, (unknown), Ryoko Motonaga, Makito Tanabe, Toshihiko Yanase	39
19	Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury 2014 ·Cardiovascular Diabetology ·Yuichi Terawaki, Takashi Nomiyama, Takako Kawanami, Yuriko Hamaguchi, Hiroyuki Takahashi, Tomoko Tanaka, (unknown), (unknown), Makito Tanabe, Toshihiko Yanase	44
20	Exendin-4, a GLP-1 Receptor Agonist, Attenuates Prostate Cancer Growth 2014 ·Diabetes ·Takashi Nomiyama, Takako Kawanami, Shinichiro Irie, Yuriko Hamaguchi, Yuichi Terawaki, (unknown), Yoko Tsutsumi, (unknown), Makito Tanabe, Hidetaka Morinaga, Tomoko Tanaka, (unknown), Kazuki Nabeshima, Masatoshi Tanaka, Toshihiko Yanase	107

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact